Abstract
This Practice Point commentary discusses a double-blind, placebo-controlled trial by Cummings et al. that investigated the effects of tibolone 1.25 mg per day in 4,534 postmenopausal women (mean age 68 years) with osteoporosis. Tibolone is a synthetic steroid with estrogenic, progestational and androgenic effects. It has been used as an alternative to estrogen to treat menopausal symptoms for 30 years. Cummings et al. found that tibolone reduced the incidence of vertebral fractures by 45%, nonvertebral fractures by 26%, breast cancer by 68% and colon cancer by 69%. The trial was discontinued 2 months before a median treatment time of 3 years because the major end point (reduction of fractures) was reached. In addition, tibolone increased the risk of stroke, although the absolute risk was small. Similarly to other compounds with estrogenic activity that increase the risk of stroke, such as estrogen and selective estrogen-receptor modulators, clinicians must weigh the risks and benefits of therapy for individual patients. This risk might be lower in women aged 50–60 years than in those aged >60 years.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kloosterboer HJ (2004) Tissue-selectivity: the mechanism of action of tibolone. Maturitas 48 (Suppl 1): S30–S40
Reed MJ and Kloosterboer HJ (2004) Tibolone: a selective tissue estrogenic activity regulator (STEAR). Maturitas 48 (Suppl 1): S4–S6
Cummings SR et al. (2008) The effects of tibolone in older postmenopausal women. N Engl J Med 359: 697–708
Rossouw JE et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321–333
Anderson GL et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291: 1701–1712
Mosca L et al. (2008) Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke [10.1161/STROKEAHA.108.518621]
Ettinger B et al. (2008) Endometrial effects of tibolone in elderly, osteoporotic women. Obstet Gynecol 112: 653–659
Author information
Authors and Affiliations
Ethics declarations
Competing interests
JC Gallagher declared associations with the following companies: Wyeth (consultant, speakers bureau and grant/research support), Lilly (grant/research support), Pfizer (grant/research support) and Schering Plough (grant-research support).
Rights and permissions
About this article
Cite this article
Gallagher, J. Does tibolone reduce the risk of fracture in older postmenopausal women with osteoporosis?. Nat Rev Endocrinol 5, 128–129 (2009). https://doi.org/10.1038/ncpendmet1063
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet1063